Crispr Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Oppenheimer cut their Q1 2020 earnings per share (EPS) estimates for Crispr Therapeutics in a report released on Monday, November 25th, according to Zacks Investment Research. Oppenheimer analyst S. Tuerkcan now forecasts that the company will post earnings of ($0.89) per share for the quarter, down from their prior forecast of ($0.87). Oppenheimer has a “Outperform” rating and a $80.00 price objective on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q2 2020 earnings at ($0.97) EPS, Q3 2020 earnings at ($1.32) EPS, Q4 2020 earnings at ($1.42) EPS, FY2020 earnings at ($4.63) EPS, FY2021 earnings at ($4.47) EPS, FY2022 earnings at ($4.98) EPS and FY2023 earnings at ($2.03) EPS.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million.

CRSP has been the subject of several other reports. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Chardan Capital reissued a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a report on Monday, November 18th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Finally, BidaskClub raised Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 30th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $69.54.

Shares of NASDAQ CRSP opened at $66.03 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The stock has a fifty day moving average price of $58.41 and a 200 day moving average price of $48.30. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $74.00. The company has a market cap of $3.72 billion, a PE ratio of -19.19 and a beta of 3.31.

In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 in the last ninety days. Corporate insiders own 21.40% of the company’s stock.

Several large investors have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. raised its stake in shares of Crispr Therapeutics by 324.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after buying an additional 1,430,364 shares during the last quarter. ARK Investment Management LLC raised its stake in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after buying an additional 701,332 shares during the last quarter. Orbimed Advisors LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth $21,167,000. Price T Rowe Associates Inc. MD raised its stake in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after buying an additional 121,176 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares during the last quarter. 49.82% of the stock is owned by institutional investors and hedge funds.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: Consumer Price Index (CPI)

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link